CN113621050A - 新型特异性结合多肽及其用途 - Google Patents

新型特异性结合多肽及其用途 Download PDF

Info

Publication number
CN113621050A
CN113621050A CN202110703906.XA CN202110703906A CN113621050A CN 113621050 A CN113621050 A CN 113621050A CN 202110703906 A CN202110703906 A CN 202110703906A CN 113621050 A CN113621050 A CN 113621050A
Authority
CN
China
Prior art keywords
glu
lys
leu
gly
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110703906.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·欣纳
A·维登曼
A·艾乐斯道夫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH filed Critical Pieris Pharmaceuticals GmbH
Publication of CN113621050A publication Critical patent/CN113621050A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
CN202110703906.XA 2014-05-22 2015-05-20 新型特异性结合多肽及其用途 Pending CN113621050A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169488.5 2014-05-22
EP14169488 2014-05-22
CN201580040321.7A CN106573964B (zh) 2014-05-22 2015-05-20 新型特异性结合多肽及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580040321.7A Division CN106573964B (zh) 2014-05-22 2015-05-20 新型特异性结合多肽及其用途

Publications (1)

Publication Number Publication Date
CN113621050A true CN113621050A (zh) 2021-11-09

Family

ID=50771150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110703906.XA Pending CN113621050A (zh) 2014-05-22 2015-05-20 新型特异性结合多肽及其用途
CN201580040321.7A Expired - Fee Related CN106573964B (zh) 2014-05-22 2015-05-20 新型特异性结合多肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580040321.7A Expired - Fee Related CN106573964B (zh) 2014-05-22 2015-05-20 新型特异性结合多肽及其用途

Country Status (14)

Country Link
US (2) US10774119B2 (enExample)
EP (2) EP3789397B1 (enExample)
JP (2) JP6753784B2 (enExample)
KR (1) KR20170004011A (enExample)
CN (2) CN113621050A (enExample)
AU (2) AU2015261968B2 (enExample)
BR (1) BR112016027024A2 (enExample)
CA (2) CA2949405C (enExample)
DK (1) DK3145945T3 (enExample)
ES (1) ES2823563T3 (enExample)
MX (2) MX384363B (enExample)
RU (1) RU2723034C2 (enExample)
SG (2) SG10201912019WA (enExample)
WO (1) WO2015177175A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805546A (zh) * 2022-06-08 2022-07-29 宁波市健康口腔医学研究院 一种检测口腔癌的t细胞表位多肽及其应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
SG11201803732PA (en) * 2015-11-30 2018-06-28 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
PT3583120T (pt) 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
JP2020530465A (ja) * 2017-08-10 2020-10-22 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2019275733B2 (en) * 2018-05-31 2025-07-31 The Chinese University Of Hong Kong Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
EP3599245A1 (en) 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
CN109206485B (zh) * 2018-09-27 2022-04-08 山东聚胜生物科技有限公司 一种防治肺癌转移的寡肽
CN109180789B (zh) * 2018-09-27 2022-08-19 上海揽微赛尔生物科技有限公司 一种寡肽及制药应用
CN109096374B (zh) * 2018-09-27 2022-11-18 深圳乐土沃森精准医疗有限公司 一种抑制肺癌转移的合成寡肽
CN109096373B (zh) * 2018-09-27 2022-06-21 江苏亨瑞生物医药科技有限公司 合成寡肽及其用途
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
AU2021269222A1 (en) * 2020-05-05 2023-01-19 Janssen Biotech, Inc. Methods of treating Crohn's disease with anti-IL23 specific antibody
WO2025226984A1 (en) * 2024-04-24 2025-10-30 Mopac Biologics, Inc. Human il-17 binding polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101611057A (zh) * 2006-06-23 2009-12-23 阿斯特拉捷利康股份公司 人il-17的抗体分子
WO2012093254A1 (en) * 2011-01-07 2012-07-12 Ucb Pharma S.A. Lipocalin 2 as a biomarker for il-17 inhibitor therapy efficacy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) * 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
MX2009009079A (es) 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA2702590A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
CA2713557C (en) * 2008-01-30 2016-06-07 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
US20110268818A1 (en) * 2008-09-18 2011-11-03 Jonathan Barasch Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
SMT201900297T1 (it) 2010-06-08 2019-07-11 Astrazeneca Ab Muteine di lipocalina lacrimale che si legano a il-4 r alfa
CN110437321A (zh) 2010-07-09 2019-11-12 阿菲博迪公司 多肽
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
DK2640740T3 (en) 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
SG10201604566QA (en) 2011-12-13 2016-07-28 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
CA2891557A1 (en) * 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
AR103714A1 (es) 2015-02-18 2017-05-31 Sanofi Sa Proteínas específicas para pioverdina y pioquelina
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101611057A (zh) * 2006-06-23 2009-12-23 阿斯特拉捷利康股份公司 人il-17的抗体分子
WO2012093254A1 (en) * 2011-01-07 2012-07-12 Ucb Pharma S.A. Lipocalin 2 as a biomarker for il-17 inhibitor therapy efficacy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAYATTE C等: "Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease", CLIN TRANSL GASTROENTEROL, vol. 3, no. 2, 16 February 2012 (2012-02-16), pages 10, XP055085226, DOI: 10.1038/ctg.2012.2 *
王晔等: "脂质运载蛋白-2的研究新进展", 复旦学报(医学版), vol. 36, no. 06, 15 November 2009 (2009-11-15), pages 782 - 785 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805546A (zh) * 2022-06-08 2022-07-29 宁波市健康口腔医学研究院 一种检测口腔癌的t细胞表位多肽及其应用
CN114805546B (zh) * 2022-06-08 2024-05-28 宁波市健康口腔医学研究院 一种检测口腔癌的t细胞表位多肽及其应用

Also Published As

Publication number Publication date
CA3170782A1 (en) 2015-11-26
AU2019201007B2 (en) 2020-10-22
US10774119B2 (en) 2020-09-15
AU2015261968A1 (en) 2016-11-24
US20200377563A1 (en) 2020-12-03
WO2015177175A2 (en) 2015-11-26
ES2823563T3 (es) 2021-05-07
CN106573964B (zh) 2021-07-16
BR112016027024A2 (pt) 2017-10-31
EP3789397A1 (en) 2021-03-10
SG10201912019WA (en) 2020-02-27
EP3145945A2 (en) 2017-03-29
DK3145945T3 (da) 2020-09-28
RU2723034C2 (ru) 2020-06-08
RU2016149596A (ru) 2018-06-26
MX2016015235A (es) 2017-06-29
WO2015177175A3 (en) 2016-02-18
US20170107266A1 (en) 2017-04-20
MX2021008318A (es) 2021-08-05
CA2949405C (en) 2023-08-01
JP6753784B2 (ja) 2020-09-09
JP2021035358A (ja) 2021-03-04
CN106573964A (zh) 2017-04-19
RU2016149596A3 (enExample) 2019-01-22
KR20170004011A (ko) 2017-01-10
EP3789397B1 (en) 2023-12-06
SG11201609274SA (en) 2016-12-29
CA2949405A1 (en) 2015-11-26
AU2019201007A1 (en) 2019-03-07
MX384363B (es) 2025-03-14
EP3145945B1 (en) 2020-07-15
AU2015261968B2 (en) 2018-11-22
JP7084965B2 (ja) 2022-06-15
US11345728B2 (en) 2022-05-31
JP2017518748A (ja) 2017-07-13

Similar Documents

Publication Publication Date Title
CN106573964B (zh) 新型特异性结合多肽及其用途
US20200148733A1 (en) Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereof
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
US11034738B2 (en) Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)
CN107820500B (zh) Cd137特异性的蛋白
US10703810B2 (en) Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211109

WD01 Invention patent application deemed withdrawn after publication